# Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/SNDX
## Company Profile
- Ticker: SNDX
- Exchange: NASDAQ
- Sector: Biotechnology
- Location: Waltham, Massachusetts
- Tags: Biopharma, Pharmaceuticals, APIs, Oncology, Hematology
## Stock Data
- Close: 22.8 USD
- Market cap: 2092082737.47 USD
- Last updated: 2026-07-17
## Business Overview
Syndax Pharmaceuticals is an oncology company focused on targeted therapies and hematologic disease opportunities. Investors watch trial readouts, regulatory milestones, and how the company converts its pipeline into commercial traction.
## Why The Stock Is Moving

SNDX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

## Geographic Base

Headquartered in Waltham, Massachusetts and listed on NASDAQ, Syndax is followed within the oncology universe for its exposure to catalyst-driven development and launch events.

## Business Model

Syndax follows a pipeline-and-launch model where data quality, approval timing, and market access determine how quickly the company can scale.

## Landscape Position

Compared with larger oncology peers, Syndax sits closer to the development side of the landscape, where each major update can move expectations quickly.

## Drug Assets

- Revuforj

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.